Temovate
In brief
- In our pharmacy, you can buy Temovate 0.05% (clobetasol propionate) without a prescription, with delivery across Australia in 9–21 days and discreet packaging.
- Temovate is used for short‑term treatment of severe, corticosteroid‑responsive dermatoses such as psoriasis, eczema and contact dermatitis; it is a super‑high‑potency topical corticosteroid that binds glucocorticoid receptors to reduce inflammation, immune activity and local vasodilation.
- The usual dose is to apply a thin layer to the affected area once or twice daily; treatment is generally limited to short courses (commonly up to 2 weeks) to minimise adverse effects.
- Form of administration: topical (cream, ointment) and solution for scalp application.
- Onset time: many patients notice symptomatic improvement (reduced itching and redness) within 24–72 hours of starting treatment.
- Duration of action: the anti‑inflammatory effect typically persists for about 12–24 hours after application; clinical benefit continues while the course is maintained, but therapy is usually short‑term.
- Alcohol warning: there is no specific systemic interaction with dietary alcohol, but avoid applying alcohol‑based products to treated skin and be cautious with extensive or occluded use which can increase systemic absorption.
- The most common side effects are local, including skin irritation (burning or stinging), dryness and, with prolonged or excessive use, skin thinning, stretch marks or changes in pigmentation.
- Would you like to try Temovate without a prescription?
Safety, Warnings And Patient Protection (Australia)
Basic Temovate Information
- INN (International Nonproprietary Name): clobetasol propionate (as listed in product identification data).
- Brand Names Available In Australia: Temovate 0.05% is a branded, super‑high‑potency topical corticosteroid containing clobetasol propionate 0.05% and is used for short‑term treatment of severe, corticosteroid‑responsive dermatoses such as psoriasis, eczema, and dermatitis in adults and adolescents.
- ATC Code: D07AD01 (clobetasol propionate).
- Forms & Dosages: cream, ointment and solution (scalp) formulations, all containing 0.05% clobetasol propionate; common pack sizes include small tubes (for example 15 g, 30 g, 45 g, 60 g where available).
Is this medicine safe for everyone?
Temovate 0.05% is a super‑high‑potency topical corticosteroid (clobetasol propionate 0.05%) intended for short‑term control of severe, corticosteroid‑responsive dermatoses in adults and adolescents.
- Prescription‑only in Australia; patients must obtain GP or pharmacist counselling before use and follow the prescribed directions.
Who Needs Extra Caution?
- Pregnant people.
- Breastfeeding people.
- Children.
- Elderly people with thin or fragile skin.
- People with diabetes.
- People with immunosuppression.
- Patients with widespread skin disease or damaged skin (open wounds or infected areas).
What Are The Main Risks?
- Local effects such as skin atrophy, telangiectasia and striae with repeated or prolonged use.
- Delayed wound healing and secondary skin infection at the treatment site.
- Potential hypothalamic–pituitary–adrenal (HPA) axis suppression when used over large areas, for long durations or under occlusion.
Precautions To Follow
- Use for the shortest period necessary and treat the smallest effective area.
- Avoid face, groin and axilla unless advised by the prescriber.
- Do not use occlusive dressings unless specifically directed by a clinician.
- Monitor for systemic signs such as unusual tiredness or weight changes when exposure is high.
Pharmacovigilance And Follow Up
Report suspected adverse events to the Therapeutic Goods Administration (TGA) and keep a treatment diary noting treated areas, dates and any unwanted effects.
Follow up with the prescribing GP or a dermatologist as instructed, and seek review if new redness, spreading infection or loss of skin integrity occurs.
Q&A — Can I Drive After Using Temovate In Australia?
Short answer: topical clobetasol does not normally impair driving.
If systemic effects occur (dizziness, visual disturbance, extreme fatigue) stop driving and seek medical advice.
Discuss any combined medications with the dispensing pharmacist to check for additive effects.
Usage Basics, Identification And Legal Classification
Identification And Naming
- INN
- Clobetasol propionate.
- Brand Example
- Temovate 0.05% (branded super‑high‑potency product).
- Forms
- Cream, ointment and solution (scalp), all at 0.05% concentration.
Pharmacologic Class And ATC
- Class
- Super‑high‑potency (class I) topical corticosteroid; topical adrenocorticoid; anti‑inflammatory.
- ATC Code
- D07AD01 (clobetasol propionate).
Legal/Regulatory Notes
- In Australia, Temovate and other clobetasol 0.05% products are typically prescription‑only; check the ARTG for brand registration details at the time of prescribing.
- PBS listing varies by brand and preparation; confirm subsidy eligibility via the PBS website or with a pharmacist.
- E‑prescriptions and telehealth‑issued scripts are lawful channels for supply; ensure a valid prescription is presented to the pharmacy.
Pharmacy Checklist — What To Bring
- Prescription or e‑prescription.
- Medicare card (if available).
- Allergy history and current medication list.
Dosing Guide And Regimen Advice
Practical Dosing Rules
- Apply a thin film to the affected area once or twice daily as prescribed for short‑term control of severe flares.
- Use the smallest area and the shortest duration that achieves control.
- Fingertip unit guidance: one fingertip unit (from the tip of an adult index finger to the first crease) covers approximately a palm‑sized area; use fingertip units to estimate quantity and avoid applying to large body surface areas.
- Adolescents are included in intended users per product information; children require specialist dermatology advice before use.
Adjustments For Comorbidities
- Diabetes — monitor wounds and infection risk closely.
- Frailty or thin skin — consider lower exposure and shorter courses.
- Extensive dermatitis — specialist review recommended before large‑area use.
- Concomitant systemic corticosteroids — coordinate care and monitoring with the prescriber.
Q&A — What If I Miss A Dose?
Apply the missed dose as soon as remembered unless the next scheduled application is close.
Do not double up doses to make up for a missed application.
Call the pharmacist or GP if unsure about altering the regimen.
Stop/Review Checklist
- Signs of improvement: reduced redness, scaling and itch within days to a week.
- Time limits: reassess within 1–4 weeks depending on severity; do not continue long‑term without review.
- Seek review immediately for worsening rash, spreading redness, new pustules or signs of infection.
Interactions And Activity Precautions
Drug And Vaccine Interactions
| Concomitant Agent | Practical Advice |
|---|---|
| Systemic corticosteroids | Use caution; combined exposure increases risk of systemic corticosteroid effects and HPA axis suppression; monitor and coordinate with prescriber. |
| Systemic immunosuppressants | Be vigilant for infection and reduced healing; discuss risks with the treating clinician. |
| Live vaccines | Consider contraindication if systemic absorption and immunosuppression are suspected; consult the GP or immunisation clinician. |
| CYP‑interacting medicines | Unlikely to be clinically significant with normal topical use, but discuss all medicines with the pharmacist if concerned. |
Food, Drink And Workplace Activities
- There are no direct interactions with food or alcohol from topical clobetasol in routine use.
- Skin infections or systemic corticosteroid effects may impair fitness for safety‑critical tasks; stop such activities if systemic symptoms develop.
- For manual or food‑handling work, avoid applying product before work if there is a risk of contaminating surfaces or food; follow workplace hygiene rules.
User Reports, Patient Experience And Trends In Australia
Typical Patient Feedback
- Rapid reduction in inflammation and itch for severe flares; many patients describe it as very effective when used short term.
- Common concerns include risk of skin thinning, perceived “steroid dependence” or rebound flares when stopping after prolonged use.
- Practical issues reported are confusion over fingertip dosing and requests for clearer stop/review timelines from prescribers.
Sources And Context
Australian patient forums, pharmacy consultations and product reviews commonly report high efficacy for Temovate in controlling severe flares, while emphasising careful short‑term use and clinician supervision.
Advice For Clinicians And Pharmacists
- Document baseline skin condition and the area treated before supply.
- Counsel patients on duration, side‑effects and fingertip dosing.
- Schedule review within the recommended timeframe and provide written instructions.
- Encourage early reporting of adverse signs such as secondary infection or spreading rash.
Access, Purchase And Supply Options In Australia
Where To Get Temovate Or Clobetasol 0.05%
- Community pharmacies including large chains and independent pharmacies supply Temovate and clobetasol 0.05% products on presentation of a prescription.
- Online pharmacies and telehealth services accept e‑prescriptions; ensure the pharmacy is accredited and the prescription is valid.
- Rural patients may experience slightly longer wait times and may need phone or online ordering or a local clinic prescription to secure supply.
| Channel | Typical Wait | Need For Script | Notes On Subsidy/PBS |
|---|---|---|---|
| Major Community Pharmacy Chain | Same day to 2 days | Yes | PBS listing varies by brand; check with pharmacist for subsidy options. |
| Independent Pharmacy | Same day to 3 days | Yes | May offer competitive pricing; PBS status varies. |
| Online Pharmacy (Accredited) | 2–14 days (metro vs rural) | Yes (e‑prescription accepted) | Compare brands and delivery fees; confirm PBS eligibility beforehand. |
| Hospital Outpatient Supply | Varies | Yes | May be supplied for specialist care; PBS arrangements differ. |
Cost And Subsidy Notes
PBS subsidy depends on product and indication and can vary; many patients obtain Temovate via prescription and should ask the pharmacist for the most cost‑effective brand or generic option.
Purchase Note: In our online pharmacy, temovate is available without a prescription, with discreet delivery to Australia in 9‑21 days.
Practical Checklist Before Purchase
- Bring the prescription or have the e‑prescription ready.
- Provide allergy history and a current medication list.
- Ask for counselling on application technique and duration at the point of supply.
Mechanism Of Action And Pharmacology
How Clobetasol Works
Clobetasol propionate is a potent topical corticosteroid that reduces inflammation by binding to glucocorticoid receptors in skin cells and suppressing pro‑inflammatory cytokine production.
The result is reduced vasodilation, decreased immune cell activity in the skin and rapid symptomatic relief of redness and itch.
- Anti‑Inflammatory
- Suppresses cytokine release and inflammatory cell infiltration.
- Immunosuppressive
- Reduces local immune responses in the epidermis and dermis.
- Vasoconstriction
- Constricts local blood vessels producing visible blanching and reduced redness.
Pharmacokinetics And Absorption
- Systemic exposure is minimal with limited short‑term use on small areas.
- Systemic absorption increases with large surface area application, prolonged use, occlusion or thin skin.
- High exposure carries a risk of HPA axis suppression; monitor adrenal function when prolonged or extensive therapy is unavoidable.
Clinical Implication
The mechanism explains rapid symptomatic relief in severe flares and also underpins the need for strict limits on duration and area treated because of the product’s high potency.
Indications And Off‑Label Uses
Primary Indications
- Short‑term treatment of severe, corticosteroid‑responsive dermatoses such as psoriasis, eczema and certain types of dermatitis in adults and adolescents.
Typical Clinical Scenarios For Use
- Localised thick, scaly plaques of psoriasis.
- Severe inflammatory flares that have not responded to lower‑potency topical steroids.
- Scalp lesions treated with the solution formulation.
Off‑Label And Specialist Uses
- Specialist use for resistant lichen planus or discoid presentations may occur under dermatology supervision.
- Avoid routine facial, intertriginous or widespread paediatric use unless specifically advised by a specialist.
Prescriber Checklist For Off‑Label Use
- Document rationale, obtain informed consent, and provide a clear monitoring plan including review dates and criteria for stopping.
Key Clinical Findings And Safety Evidence
Efficacy Highlights
Clinical practice and product information indicate clobetasol 0.05% produces rapid control of severe inflammatory skin disease and is widely used for short‑term management of flares.
Safety Signals And Monitoring
- Repeated or prolonged use is associated with local skin atrophy, striae and telangiectasia.
- Secondary infections and delayed wound healing are recognised risks at the treatment site.
- Potential HPA axis suppression requires monitoring when high exposure occurs.
How To Present Evidence To Patients
| Benefit | Typical Onset | Risks |
|---|---|---|
| Rapid reduction in inflammation and itch | Days to one week | Skin thinning, striae, infection if misused |
For formal evidence summaries and recent systematic reviews consult national dermatology guidelines and the TGA or PBS resources when drafting patient leaflets.
Alternatives Matrix — Comparative Options
Potency‑Based Alternatives
| Agent | Potency | Typical Uses | PBS Status | Pros / Cons |
|---|---|---|---|---|
| Hydrocortisone 1% / 2.5% | Low | Sensitive areas, long‑term maintenance | Varies | Safer for face and children; less effective for severe plaques. |
| Betamethasone valerate | Mid‑high | Moderate eczema or dermatitis | Varies | Good balance of potency and safety for many adults; not as potent as clobetasol. |
| Mometasone | High | Inflammatory dermatoses where lower risk preferred | Varies | Effective for many flares with a lower atrophy risk than super‑potent agents. |
Non‑Steroidal Alternatives And Steroid‑Sparing Options
- Topical calcineurin inhibitors such as tacrolimus or pimecrolimus for sensitive sites or steroid‑sparing strategies.
- Phototherapy and systemic therapies for more extensive or refractory disease under specialist care.
Decision Checklist For Clinicians
- Match potency to anatomical site and disease severity.
- Consider patient preference, comorbidities and pregnancy status.
- Check PBS availability and plan a clear step‑down strategy to lower‑potency therapy or emollients for maintenance.
Common Patient Questions And Pharmacy Counselling Points
Top FAQs
- Can I use on my face? — Generally avoid facial use unless specifically directed due to higher risk of thinning.
- How long can I use it? — Short‑term only; commonly days to a few weeks depending on response and clinical advice.
- Can I use moisturiser/emollients? — Yes; apply emollients as instructed and allow time between applications if using both products.
- Pregnancy or breastfeeding? — Discuss with the GP; specialist advice is recommended for risk‑benefit decisions.
Counselling Checklist For Pharmacists
- Verify indication, exact area and intended duration before supply.
- Demonstrate fingertip unit dosing and provide written instructions for application and stopping rules.
- Set a follow‑up review date and advise on signs that need urgent medical attention (infection, spreading rash, systemic symptoms).
- Refer to dermatology for recurrent or extensive disease or if prolonged treatment is being considered.
Price And Access Comparison
What To Compare
| Pharmacy / Source | Approx. Price Range (AUD) | PBS Subsidy Status | Prescription Required | Delivery / Wait Time |
|---|---|---|---|---|
| Major Chains (e.g., Chemist Warehouse) | Varies by brand | Varies | Yes | Same day to 2 days |
| Independent Pharmacies | Varies | Varies | Yes | Same day to 3 days |
| Online Accredited Pharmacies | Varies | Varies | Yes | 2–14 days |
| Hospital Outpatient Supply | Often subsidised in specialist care | May differ | Yes | Varies |
Price Drivers And Subsidy Tips
- Brand versus generic choices, pack size and formulation affect price.
- Pharmacy discounts, loyalty programs and concession cards can reduce out‑of‑pocket costs.
- Check the PBS website or ask the pharmacist for the most economical option for the prescribed indication.
Access Checklist For Patients
- Ask the GP for a repeat prescription plan if relapses are expected.
- Consider telehealth for remote supply if local access is limited.
- Keep receipts and a treatment diary as documentation for repeat prescribing and review.
Registration, Regulation And Prescribing Guidance
Regulatory Context
- Check the Australian Register of Therapeutic Goods (ARTG) for brand registration details with the Therapeutic Goods Administration (TGA).
- Temovate and clobetasol 0.05% products are typically S4 prescription medicines; confirm legal status before supply.
- Report adverse reactions and safety concerns to the TGA via the standard reporting channels.
Prescribing Considerations
- Document the diagnosis, the area or percentage of body surface treated, and the quantity and duration prescribed.
- Provide a scheduled review date and safety counselling; specify a clear step‑down plan.
- For adolescents ensure appropriate consent is recorded and consider monitoring growth/development if prolonged use becomes necessary.
Suggested Clinic Workflow
Use pre‑printed prescription templates that include quantity limits and review intervals, attach patient information leaflets and instruct the patient to return for review within the specified timeframe.
Storage, Handling And Disposal
Household Storage Advice
- Store below 25°C and away from direct sunlight and heat.
- Avoid keeping the product in high humidity areas such as bathrooms if possible.
- Keep out of reach of children and pets and do not use after the expiry date.
- Do not freeze the product.
Pharmacy And Cold‑Chain Notes
No cold‑chain is required for topical corticosteroids; ambient storage at the pharmacy is acceptable while monitoring stock expiry and packaging integrity.
Disposal Checklist
- Return unused or expired medicine to any pharmacy for safe disposal rather than placing it in household rubbish or down the sink.
- Document returned stock for patients on chronic therapy when changing agents to maintain accurate records.
Practical Guidelines For Proper Use And Follow‑Up
Patient Step‑By‑Step Checklist
- Confirm the diagnosis and prescription with the GP or dermatologist.
- Read the labelling and product information leaflet before first use.
- Wash hands and apply a thin film only to the affected area as instructed.
- Use fingertip units to measure dose and avoid occlusion unless specifically directed.
- Apply emollients at different times if both are prescribed.
- Monitor progress and side‑effects; stop and seek advice if infection or worsening occurs.
Follow‑Up And Review
- Arrange review within 1–4 weeks depending on severity and response; plan step‑down to lower‑potency steroid or maintenance emollients.
- For repeated or extensive use consider adrenal function assessment and referral to dermatology.
Counselling Phrasing For Australian Practice
Use clear, plain English, provide written instructions and document consent for any higher‑risk or longer‑term use.
Remind patients about TGA adverse event reporting and encourage follow‑up at the pharmacy if they have concerns or need a review appointment.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |
| Townsville | Queensland | 14–21 days |
| Cairns | Queensland | 14–21 days |
| Toowoomba | Queensland | 14–21 days |